You are here: Industry Insights > ViiV Healthcare

News List

ViiV Healthcare's Dovato approved in US as first two-drug single-tablet regimen for patients with treatment-naïve HIV firstwordpharma
April 09, 2019
The FDA on Monday announced the approval of ViiV Healthcare's Dovato (dolutegravir/lamivudine) for ^
ViiV announces long-term positive results for Juluca combination pharmaceutical-technology
April 09, 2019
London-based ViiV Healthcare has announced three-year results from its Sword-1 and Sword-2 trials.
Viiv files HIV drug patent infringement lawsuit against Gilead pharmaceutical-technology
February 11, 2018
GSK-owned Viiv healthcare has filed a lawsuit against Gilead, the American biopharma company, for an alleged patent infringement of an HIV drug which has been newly approved.
FDA approves two-drug regimen, JULUCA for the Treatment of HIV-1 Infection biospace
November 23, 2017
HIV patients have a new maintenance drug in their arsenal of medication.
ViiV Healthcare submits regulatory applications for HIV two-drug regimen europeanpharmaceuticalreview
June 07, 2017
GSK and ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, have announced regulatory submissions...
ViiV study shows efficacy of two-drug HIV regimen pharmatimes
February 16, 2017
ViiV Healthcare has unveiled late-stage data showing that an experimental two-drug regimen of its dolutegravir and Janssen Science's rilpivirine was comparable in efficacy to three- or four-drug antiretroviral regimens in virologically suppressed patients

Previous page 1 2 3 Next page